From biologics to small-molecule modulators: the evolving landscape of interleukin-targeted therapeutics.

Zhu Y, He Q, Chen Y, Lu T, Lu S

Open source

DOI
10.1016/j.drudis.2026.104728
Published
2026 Jul
Container
Drug discovery today
Publisher
Not recorded
Open access
no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.drudis.2026.104728,
  title = {From biologics to small-molecule modulators: the evolving landscape of interleukin-targeted therapeutics.},
  author = {Zhu Y and He Q and Chen Y and Lu T and Lu S},
  year = {2026},
  journal = {Drug discovery today},
  doi = {10.1016/j.drudis.2026.104728},
  url = {https://doi.org/10.1016/j.drudis.2026.104728}
}

RIS

TY  - JOUR
TI  - From biologics to small-molecule modulators: the evolving landscape of interleukin-targeted therapeutics.
AU  - Zhu Y
AU  - He Q
AU  - Chen Y
AU  - Lu T
AU  - Lu S
PY  - 2026
JO  - Drug discovery today
DO  - 10.1016/j.drudis.2026.104728
UR  - https://doi.org/10.1016/j.drudis.2026.104728
ER  - 

APA

Y, Z., Q, H., Y, C., T, L., & S, L. (2026). From biologics to small-molecule modulators: the evolving landscape of interleukin-targeted therapeutics.. Drug discovery today. https://doi.org/10.1016/j.drudis.2026.104728

Source records